| Ytd | 89.25% | |
| 1y | 120.40% |
| Open | 77.12 | Prev Close | 77.24 | Low | 76.00 | High | 78.30 | Mkt Cap | 6.08B |
| Vol | 27.36K | Avg Vol | 748.37K | EPS | 0.99 | P/E | 78.75 | Forward P/E | 47.75 |
| Beta | 0.09 | Short Ratio | 7.98 | Inst. Own | 100.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 74.29 | 200-d Avg | 54.47 | 1yr Est | 98.00 |
KNSA News
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for cont
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight a
Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se
US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Ph
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 mil
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raise
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 mil
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.27 per share which beat the
Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Kiniksa Pharmaceuticals (NASDAQ:KNSA) sees FY2026 sales of $900.000 million-$920.000 million vs $902
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.17 per share which missed th
Canaccord Genuity analyst Edward Nash initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
ARCALYST (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you
Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1